Hanmi Investigative Site
Chula Vista, California, 91911, United States
NCT Number: NCT03374241
Single ascending dose of HM15211 in healthy obese subjects.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Chula Vista, California, 91911, United States
A First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics after single ascending dose of HM15211 in healthy obese subjects.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Long-acting tri-agonist
Time frame: 1 month
An adverse event is any undesirable and unintended medical event occurring to a subject in a clinical study, whether or not related to the investigational products
Hanmi Pharmaceutical Company Limited
Industry
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211(Efocipegtrutide) in Healthy Obese Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00862433
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT00065676
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT05093634
Body Weight, Genetic Obesity
Phoenix, Arizona, United States
View Trial DetailsNCT06066528
Body Weight, Diabetes Mellitus
Anniston, Alabama, United States
View Trial Details